THE PIAGGIO GROUP AND FOTON MOTOR GROUP SIGN A GENERAL AGREEMENT FOR JOINT DEVELOPMENT OF A NEW ELECTRICALLY POWERED LIGHT COMMERCIAL VEHICLE

BEIJING, Dec. 9, 2022 /PRNewswire/ — The Chairman and CEO of Piaggio & C. S.p.A. (PIA.MI), Roberto Colaninno, and the Vice General Manager of Foton Motor Group, Wang Shuhai, signed a preliminary agreement in Mantua for the development of a new range of four-wheel electric light commercial vehicles. The agreement consolidates the partnership set up by the two groups in September 2017 for joint development of innovative solutions for the light commercial vehicles market.

Over the coming months, a team of representatives from the two groups will work on the development and approval of a production and commercial plan and on the contractual documents with a view – in the event of a successful outcome of the above activities – to finalising the technical documentation for the project and the contracts by Spring 2023.

Park Place Technologies Acquires CentricsIT Global Services Division

Purchase Strengthens Park Place as Global Leader for all IT Infrastructure Solutions, as Economy and Skills Gap Challenges Impact Global Business.

CLEVELAND, Dec. 08, 2022 (GLOBE NEWSWIRE) — Park Place Technologies, the leading global data center and networking optimization firm, has acquired the TPM and Professional Services assets of CentricsIT, an IT services provider based in Atlanta, Georgia.

The demand for Professional Services is growing globally, driven by economic conditions and skills gaps. Park Place’s Professional Services offering will benefit from the acquisition with greater capabilities in IMAC, ITAD, Remote Hands, and deployment services, including cabling, wi-fi surveys, data center installs and refreshes, and network installations. Park Place clients will benefit from a state-of-the-art Professional Services portal developed by CentricsIT that provides real-time project status, reporting, and collaboration tools. Park Place’s Project Management Office function will be enhanced with the addition of Project Management Institute-certified CentricsIT employees worldwide. CentricsIT customers will gain access to Park Place Technologies’ unique portfolio of products and services, including automated monitoring and managed services.

Chris Adams, President and CEO of Park Place Technologies, said in addition to investing in Professional Services, Park Place continues to focus on providing exceptional customer service and support. “When acquiring businesses, we always search for companies that are intensely focused on customer service and have a similar culture and value set to PPT. CentricsIT delivers that and more,” he said. “Our combined Professional Services capabilities are evolving to meet client needs, and this will accelerate that CX agenda. CentricsIT’s EVP of Global Services, Patrick Keuller, will join the global Professional Services group. Patrick brings decades of experience and understands the growing needs of companies around the globe that are struggling to recruit skilled stafff and stretching budgets to efficiently manage their infrastructures.”

CentricsIT has been a global leader in IT lifecycle management solutions and professional services since 2007. As the company transitions its professional services and TPM divisions to Park Place Technologies, it will retain its server, storage and networking resale division.

“We’re pleased to have found the right fit in Park Place Technologies for our services practice to grow and thrive,” said CentricsIT founder and CEO Derek Odegard. “We know they will continue to excel in service delivery and client support.”

This is Park Place’s fourth acquisition in 2022.

“Agile Equity provided investment banking services to CentricsIT and facilitated the transaction,” Odegard said. “We enjoyed working with the Agile Equity team. Their expertise in the data center infrastructure industry was very beneficial throughout the transaction.”

Founded in 1991, Park Place Technologies is powered by the world’s largest on-the-ground engineering team, a robust group of hundreds of advanced engineers and its fully staffed 24x7x365 Enterprise Operations Center. Park Place leverages a global parts supply chain, automation, machine learning and a comprehensive portfolio of services and products to optimize networking and data center uptime and performance.

About Park Place Technologies

Park Place Technologies is a global data center and networking optimization firm. Powered by the world’s largest on-the-ground engineering team, a robust group of advanced engineers and our fully staffed, 24x7x365 Enterprise Operations Center, we offer a robust portfolio of IT solutions to optimize networking and data center uptime and performance. Our services include third-party data center hardware maintenance, professional services, infrastructure managed services, network performance monitoring and hardware sales. Through our unique and fully integrated DMSO (Discover, Monitor, Support, Optimize) approach, customers enjoy streamlined infrastructure monitoring and management, cost efficiencies, less chaos, and faster mean-time-to-resolution – ultimately providing the freedom to think bigger. Park Place’s industry-leading and award-winning services include Park Place Hardware Maintenance™, Park Place Professional Services™, ParkView Managed Services™, Entuity Software™ and Curvature Hardware sales. For more information, visit www.parkplacetechnologies.com. Park Place is a portfolio company of Charlesbank Capital Partners and GTCR.

Jennifer Deutsch
Park Place Technologies
(440) 991-3105
jdeutsch@parkplacetech.com

Michael Miller
Park Place Technologies
(440) 991-5509
mmiller@parkplacetech.com

GlobeNewswire Distribution ID 8711279

POWERCHINA offre un nouvel exemple de coopération Chine-Côte d’Ivoire au profit du peuple

PÉKIN, 8 décembre 2022 /PRNewswire/ — Un reportage de : CRI Online :

POWERCHINA met en œuvre les concepts de consultation approfondie, de contribution conjointe et de bénéfices partagés, avec tout son cœur et sa sincérité, en Côte d’Ivoire, un pays d’Afrique de l’Ouest éloigné de la mer. La centrale hydroélectrique de Gribo-Popoli construite par POWERCHINA fera du fleuve de Sassandra un nouveau moteur pour le développement socio-économique du pays et de ses voisins.

Ce projet contribuera à atténuer la pénurie d’électricité en Côte d’Ivoire et jouera un rôle positif dans la promotion du développement du Pool énergétique d’Afrique de l’Ouest. Parallèlement, le projet permettra d’économiser de précieuses ressources énergétiques fossiles, de réduire la pollution de l’environnement et d’atténuer la pression environnementale. En outre, il pourra également stimuler efficacement le taux d’emploi, augmenter les recettes fiscales et promouvoir le développement des industries des matériaux et des services de construction. Son exploitation apportera de plus grands avantages sociaux et économiques, jouant un rôle important dans la promotion de l’économie ivoirienne.

Actuellement, différents axes de travail sont en cours de traitement, tels que la construction de l’usine, du déversoir, du barrage, du batardeau, l’excavation de roche et la construction temporaire. Les entreprises de construction ont travaillé ardemment pour surmonter les difficultés technologiques, les conditions géologiques locales complexes, et l’épidémie, reliant les rêves des deux peuples avec la valeur de vivre en harmonie avec les différences.

Kouamo, ingénieur de projet ivoirien, a été encouragé par POWERCHINA, ses avantages à la pointe du secteur et ses riches expériences. Il a exprimé sa profonde gratitude pour la culture d’entreprise et s’est réjoui de la poursuite de la coopération dans les projets de POWERCHINA à l’avenir.

Vaccine R&D Leader Kathrin Jansen and Immunologist Kizzmekia Corbett Awarded Sabin’s Gold Medal and Rising Star Respectively

The Albert B. Sabin Gold Medal and Rising Star Award

The Sabin Vaccine Institute awarded R&D leader Dr. Kathrin Jansen the 2022 Gold Medal for her extraordinary contributions to vaccinology. Immunologist Dr. Kizzmekia Corbett received the 2022 Rising Star award for her work advancing the field of immunization.

WASHINGTON, Dec. 07, 2022 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute today honored two extraordinary scientists for their breakthrough vaccine research that changed the course of the COVID-19 pandemic, advanced public health, and saved countless lives. The 2022 Albert B. Sabin Gold Medal was awarded to vaccine research leader Kathrin U. Jansen, PhD, and the Rising Star to immunologist Kizzmekia Corbett, PhD.

The Gold Medal, now in its 29th year, is Sabin’s highest scientific honor, given annually to a distinguished member of the global health community who has made exceptional contributions to vaccinology or a complementary field. Past award recipients include leaders of vaccinology and vaccine advocacy such as Drs. Barney Graham, Carol Baker, Anne Gershon, Bill Foege, and Myron Levine.

Dr. Jansen was selected for her nearly three decades of commitment to advancing vaccine research and development (R&D) for a range of challenging diseases from COVID-19 to HPV and pneumonia, all of which afflict adults and children in low-and middle-income countries with already fragile health care systems.

This past August, Dr. Jansen retired as the senior vice president and head of vaccine research and development at Pfizer Inc. There, Dr. Jansen led global vaccines R&D with responsibilities ranging from discovery to post-marketing commitments. In collaboration with BioNTech, Dr. Jansen spearheaded the development of a COVID-19 vaccine that would become the first FDA and WHO-authorized COVID-19 vaccine and is the first-ever approved vaccine to use an mRNA platform.

Dr. Jansen’s leadership at Pfizer also produced newer versions of a widely used pneumococcal conjugate vaccine and vaccine candidates to prevent Streptococcus pneumoniae, respiratory syncytial virus (RSV), meningococcal infections, and Group B streptococcus. Previously, she directed vaccine R&D efforts at Merck Research Laboratories and led the development of the world’s first cervical cancer vaccine. She also contributed to programs for rotavirus, mumps, measles and rubella.

“We are delighted to recognize Dr. Jansen with our Gold Medal award for her commitment to furthering vaccines and tackling tough scientific challenges in the interest of benefitting humanity and saving lives,” says Amy Finan, Sabin’s chief executive officer. “Throughout her career, she has demonstrated a unique passion for answering perplexing research questions and making bold decisions that led to impactful public health milestones.”

Dr. Jansen said she was “humbled” by the honor. “When you look at all the previous Gold Medal recipients, they are colleagues and friends that you know and have interacted and worked with for years – passionate people, all dedicated to making a healthier world.”

Sabin’s Rising Star Dr. Corbett is an assistant professor of immunology and infectious diseases at Harvard T.H. Chan School of Public Health. A viral immunologist by training, Dr. Corbett works to advance vaccine development for pandemic preparedness and to build public confidence in vaccines, particularly among communities of color facing health disparities. While at the National Institutes of Health she was a member of the team whose research on the novel coronavirus laid the groundwork for the COVID-19 Moderna vaccine – the first candidate to be tested in Phase 1 clinical trials in the U.S.

Dr. Corbett’s research has also included a universal influenza vaccine, dengue, and respiratory syncytial virus. Currently, she leads a laboratory focused on novel coronaviruses and other infectious diseases that aims to inform vaccine development against potential future pandemics. She is also a leading advocate for STEM education, health care equity, and community-based public health outreach.

“Sabin is delighted to name Dr. Corbett this year’s Rising Star,” says Finan. “Her contributions to vaccine development are matched only by her dedication to shoring up vaccine confidence, especially among skeptics. She has done incredible work explaining the scientific rigor behind vaccines and is inspiring the next generation of researchers and public health heroes.”

“It’s a really big honor for me to win this award,” says Dr. Corbett. “Having just started my career and my own lab, winning this Rising Star Award suggests that – number one – I have a long way to go but – number two – that I am capable, which is especially good to hear from my peers, mentors and other more experienced scientists.”

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world.

For more information, visit https://www.sabin.org/ and follow us on Twitter @sabinvaccine.

Media contact: Rajee Suri, rajee.suri@sabin.org

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/66127064-3ffb-4f40-9010-7d9da33b625b

GlobeNewswire Distribution ID 8708580

Kathrin Jansen, Líder de Pesquisa e Desenvolvimento de Vacinas, e Kizzmekia Corbett, Imunologista, Premiadas com as Medalhas Gold e Rising Star da Sabin, respectivamente

WASHINGTON, Dec. 07, 2022 (GLOBE NEWSWIRE) — O Sabin Vaccine Institute homenageou hoje duas cientistas extraordinárias pelas suas pesquisas inovadoras sobre vacinas que mudaram o curso da pandemia da COVID-19, avançaram a saúde pública e salvaram inúmeras vidas. A Gold Medal Albert B. Sabin de 2022 foi concedida à líder de pesquisa de vacinas Kathrin U. Jansen, PhD, e a Rising Star à imunologista Kizzmekia Corbett, PhD.

A Gold Medal, agora no seu 29º ano, é a maior honra científica da Sabin, concedida anualmente a um membro distinto da comunidade de saúde global pelas suas contribuições excepcionais para o campo de vacinação ou complementar. Os vencedores dos prêmios anteriores incluem líderes de vacinação e defesa de vacinas como os Drs. Barney Graham, Carol Baker, Anne Gershon, Bill Foege e Myron Levine.

A Dra. Jansen foi selecionada por suas quase três décadas de compromisso com o avanço da pesquisa e desenvolvimento de vacinas (P&D) para uma série de doenças desafiadoras, desde COVID-19 até HPV e pneumonia, que afetam adultos e crianças de países de baixa e média renda com sistemas de saúde já frágeis.

Em agosto passado, a Dra. Jansen se aposentou como vice-presidente sênior e chefe de pesquisa e desenvolvimento de vacinas da Pfizer Inc, onde liderou a pesquisa e desenvolvimento de vacinas globais com responsabilidades que vão desde a descoberta até os compromissos pós-comercialização. Em colaboração com a BioNTech, a Dra. Jansen liderou o desenvolvimento da primeira vacina em uma plataforma de mRNA contra a COVID-19 a ser autorizada pela FDA e pela OMS.

A liderança da Dra. Jansen na Pfizer também resultou em versões mais recentes de uma vacina pneumocócica conjugada amplamente usada e candidatos a vacina para prevenir o Streptococcus pneumoniae, vírus sincicial respiratório (VSR), infecções meningocócicas, e o estreptococo do Grupo B. Anteriormente, ela dirigiu os esforços de pesquisa e desenvolvimento de vacinas na Merck Research Laboratories e liderou o desenvolvimento da primeira vacina contra o câncer de colo do útero do mundo. Ela também contribuiu para programas de rotavírus, caxumba, sarampo e rubéola.

“Estamos muito contentes em conceder à Dra. Jansen o nosso prêmio Gold Medal por sua dedicação à promoção das vacinas e ao enfrentamento de desafios científicos visando beneficiar a humanidade e salvar vidas”, disse Amy Finan, diretora executiva da Sabin. “Ao longo da sua carreira, ela demonstrou um entusiasmo único por responder a perguntas de pesquisa desconcertantes e tomar decisões ousadas que levaram a marcos impactantes para a saúde pública.”

A Dra. Jansen disse que se sentiu “honrada” com a premiação. “Os ganhadores anteriores da Gold Medal são colegas e amigos com os quais eu interagi e trabalho com eles há anos – pessoas entusiasmadas, dedicadas a tornar o mundo mais saudável para todos.”

A Dra. Corbett, recebedora do prêmio Rising Star da Sabin, é professora assistente de imunologia e doenças infecciosas da Harvard T.H. Chan School of Public Health. Imunologista viral, a Dra. Corbett trabalha para promover o desenvolvimento de vacinas em antecipação às pandemias e para aumentar a confiança do público nas vacinas, particularmente entre comunidades de pessoas de cor que enfrentam disparidades de saúde. No National Institutes of Health ela foi membro da equipe cuja pesquisa sobre o novo coronavírus lançou as bases para a vacina COVID-19 Moderna – a primeira candidata a ser testada em ensaios clínicos de Fase 1 nos EUA.

A pesquisa da Dra. Corbett também incluiu uma vacina universal contra a gripe, dengue e vírus sincicial respiratório. Atualmente ela lidera um laboratório focado nos novos coronavírus e outras doenças infecciosas, visando informar o desenvolvimento de vacinas contra possíveis pandemias futuras. Ela também é uma das principais defensoras da educação STEM, da equidade nos cuidados de saúde, e do alcance da saúde pública nas comunidades.

“A Sabin tem o prazer de premiar a Dra. Corbett com o Rising Star deste ano”, disse Finan. “Sua contribuição para o desenvolvimento da vacina acompanha sua dedicação em aumentar a confiança nas vacinas, especialmente entre os céticos. Ela fez um trabalho incrível explicando o rigor científico por trás das vacinas, inspirando a próxima geração de pesquisadores e heróis da saúde pública.”

“É uma grande honra para mim ganhar este prêmio”, disse a Dra. Corbett. “O recebimento deste Prêmio Rising Star no início da minha carreira no meu próprio laboratório sugere que – primeiro – tenho um longo caminho a percorrer, mas – segundo– que sou capaz. E isso é especialmente bom de ouvir dos meus colegas, mentores e outros cientistas mais experientes.”

Sobre o Sabin Vaccine Institute

O Sabin Vaccine Institute é um dos principais defensores da expansão do acesso e uso de vacinas em todo o mundo, do avanço da pesquisa e desenvolvimento de vacinas e da ampliação do conhecimento e inovação das vacinas. Revelando o potencial das vacinas através da parceria, o Sabin criou um ecossistema robusto de financiadores, inovadores, implementadores, profissionais, formuladores de políticas e partes interessadas públicas para avançar sua visão de um futuro livre de doenças evitáveis. Como uma organização sem fins lucrativos com mais de duas décadas de experiência, o Sabin está empenhado em encontrar soluções duradouras que levem todos os benefícios das vacinas a todas as pessoas, independentemente de quem sejam ou de onde vivem. No Sabin, acreditamos no poder das vacinas para mudar o mundo.

Para mais informação, visite https://www.sabin.org/ e siga-nos no Twitter @SabinVaccine.

Contato com a Mídia: Rajee Suri, rajee.suri@sabin.org

Foto deste comunicado disponível em: https://www.globenewswire.com/NewsRoom/AttachmentNg/66127064-3ffb-4f40-9010-7d9da33b625b

GlobeNewswire Distribution ID 8709489